The hypoxic inducible stress response as a target for cancer drug discovery.
about
Expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and matrix metalloproteinase-2 in sacral chordomasTargeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabProteomics in pancreatic cancer research.Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma.Activation of AMP-Activated Protein Kinase α and Extracelluar Signal-Regulated Kinase Mediates CB-PIC-Induced Apoptosis in Hypoxic SW620 Colorectal Cancer CellsInhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells.Gemcitabine in the treatment of metastatic pancreatic cancer.mRNA Expression Profiles for Prostate Cancer following Fractionated Irradiation Are Influenced by p53 StatusAdvanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.HAF : the new player in oxygen-independent HIF-1alpha degradation.Why target PIM1 for cancer diagnosis and treatment?Progress and contrasts of the development of tivozanib for therapy of kidney cancer.Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1α inactivation in hypoxic PC-3 prostate cancer cells.The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells.Early effects of doxorubicin in perfused heart: transcriptional profiling reveals inhibition of cellular stress response genes.
P2860
Q33274511-AD4475BB-5FE2-4B57-A4A6-CC8E5554F385Q33418562-FA26EC59-E69F-4130-8FE5-BBD0ED88B9E0Q33791981-9DBFFA1B-731A-404C-BE48-E442740AFB59Q35570450-A65E43BC-67CC-4059-9AA5-C9DAA38E7965Q36074228-70F44232-BB66-4466-9FB3-4EAB5BB39D00Q36755014-DF5AFE68-E2C7-4B0B-B032-B9DDCE5970E0Q37024427-DD083438-6AC5-4514-AB34-83096303F4F9Q37134412-4CBCB46A-4C26-4164-B6AC-0D9211352E54Q37246446-5DD2DAF4-2F1A-4A64-BB66-2741680EDC0DQ37268981-2EB4329D-116E-4D29-B775-B487FA69146AQ37450692-4AABAD58-914D-4AFB-A532-311714CD66EAQ37797472-3593C6B8-433F-4CAF-A10C-6CB15E5CDDE6Q37958038-C9342F68-41E6-43A0-8AD9-6C11BD034680Q38894617-880DEBAE-A809-4048-823F-C983DFE8A9E4Q39578109-A930DAEC-C8FC-43BC-AF75-436C3088C003Q39989937-33FE0FB4-8FDF-4943-8FA6-83821CA8D4D5Q43201120-4C041974-D299-4BB1-B4AC-B84EDA2BB281
P2860
The hypoxic inducible stress response as a target for cancer drug discovery.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The hypoxic inducible stress response as a target for cancer drug discovery.
@ast
The hypoxic inducible stress response as a target for cancer drug discovery.
@en
type
label
The hypoxic inducible stress response as a target for cancer drug discovery.
@ast
The hypoxic inducible stress response as a target for cancer drug discovery.
@en
prefLabel
The hypoxic inducible stress response as a target for cancer drug discovery.
@ast
The hypoxic inducible stress response as a target for cancer drug discovery.
@en
P1433
P1476
The hypoxic inducible stress response as a target for cancer drug discovery.
@en
P2093
Mei Yee Koh
Sarah J Welsh
P304
P356
10.1053/J.SEMINONCOL.2006.04.011
P50
P577
2006-08-01T00:00:00Z